Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

NCT02351856 ·Status: COMPLETED ·Phase: PHASE2

Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

NCT03417830 ·Status: TERMINATED ·Phase: PHASE1

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

NCT05442047 ·Status: COMPLETED ·Phase: PHASE2

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903 ·Status: RECRUITING ·Phase: PHASE3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811 ·Status: RECRUITING ·Phase: PHASE3

EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

NCT06194825 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

NCT05758493 ·Status: RECRUITING ·Phase: PHASE2

Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

NCT05635045 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

NCT04814186 ·Status: COMPLETED ·Phase: PHASE4

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

NCT05233163 ·Status: COMPLETED ·Phase: PHASE4

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

NCT06260709 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

NCT06393465 ·Status: COMPLETED

Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

NCT07213583 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

NCT03702829 ·Status: TERMINATED ·Phase: PHASE2

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

NCT02791230 ·Status: COMPLETED ·Phase: PHASE3

A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

NCT07235462 ·Status: RECRUITING

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353 ·Status: TERMINATED ·Phase: PHASE2

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

NCT05577819 ·Status: RECRUITING ·Phase: NA

NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis

NCT06251778 ·Status: RECRUITING

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

NCT01994889 ·Status: COMPLETED ·Phase: PHASE3

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

NCT06321523 ·Status: COMPLETED